Skip to content

Study · Not a test of the peptide alone · 1999

1 result

Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins.

Rozen F, Pollak M

International journal of oncology1 Sept 1999Cited by 21 (Europe PMC)

PMID10427145 (opens in a new tab)DOI10.3892/ijo.15.3.589 (opens in a new tab)PepBankPUB-10427145
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 01LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In MCF-7 cells, EB1089 did not inhibit IRS-1 tyrosine phosphorylation induced by des(1‑3) IGF-I.

    In plain wordsIn cells, EB1089 did not inhibit IRS-1 phosphorylation induced by des(1‑3) IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeIRS-1 tyrosine phosphorylation
    Study

    n: not reported in source

    MCF-7 breast cancer cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    However, EB1089 does not inhibit tyrosine phosphorylation of IRS-1 induced by des(1-3) IGF-I, an IGF-I analogue with greatly reduced affinity for IGFBPs.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.